PF-06741086 Long-term Treatment in Severe Hemophilia

Протокол NCT03363321
Описание
Статус выполнения
completedResults
Ход выполнения
100%
30.05.2018
05.08.2020
Заболевания
Цели
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
Организация, проводящая КИ
Pfizer
Фаза КИ
II
Количество пациентов
20

Новости и обновления